# Lumason® Infusion vs. Bolus Administrations

> **NCT06400004** · PHASE3 · RECRUITING · sponsor: **Bracco Diagnostics, Inc** · enrollment: 106 (estimated)

## Conditions studied

- Heart Diseases

## Interventions

- **DRUG:** Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
- **DRUG:** Lumason

## Key facts

- **NCT ID:** NCT06400004
- **Lead sponsor:** Bracco Diagnostics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06400004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06400004, "Lumason® Infusion vs. Bolus Administrations". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06400004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*